Processing .....please wait.. 
The article has been forwarded.... 
Cadila eyes overseas acquisitions to boost growth
Monday, 19 January 2004, 20:30 IST
NEW DELHI: Leading pharmaceutical and healthcare solutions provider Cadila is eyeing overseas acquisitions, particularly in the US and Europe, to double turnover in two years from the current 
5.5 billion.
"In two years we hope to double our turnover through inorganic kind of acquisition. We are keen to target the biggest generic drug market in the US and Europe," Cadila Pharmaceuticals Ltd vice president (marketing) J.P. Parswani told reporters here Saturday.
Through technical tie-ups with companies upward of 1.4 billion generic drugs strength in areas like diabetes, cardiovascular problems and gastroenteritis, Cadila sees potential for better market acceptability post 2005 when the new patent regime under TRIPS (Trade Related Intellectual Property Rights) comes into force.
"Many of the companies overseas are looking for such tie-ups," said Parswani, hinting that Cadila is in the advanced stages of such an acquisition in the US.
As part of a continuing medical education programme, Cadila had organised a seminar to update leading gastroenterologists in the country on the latest development in the line of treatment for gastric ulcers and esophagitis.
One of the most common health problems worldwide, it is estimated that around 10 percent of people suffer from pain in the abdomen. In India too, this is a widely prevalent problem.
"The most important breakthrough in medicine has been the development of rabeprazole for acid control, which is at the root of the gastroenterological problems," said Parswani.
After two-years of clinical trials, Cadila is getting ready to commercially launch the intravenous (IV) version of its Rabeloc brand of rabeprazole drug.
"Extensive trials are underway and the initial results are very encouraging," said Arun Maseeh, medical head of Cadila Pharmaceuticals.
With the expected launch of the IV drug, Cadila would be the first globally to come out with a drug delivery system that promises quicker and safer treatment management for people who are not able to take rabeprazole drug orally.
The company is also focusing on life sciences to pilot growth.
Source: IANS
5.5 billion.
"In two years we hope to double our turnover through inorganic kind of acquisition. We are keen to target the biggest generic drug market in the US and Europe," Cadila Pharmaceuticals Ltd vice president (marketing) J.P. Parswani told reporters here Saturday.
Through technical tie-ups with companies upward of 1.4 billion generic drugs strength in areas like diabetes, cardiovascular problems and gastroenteritis, Cadila sees potential for better market acceptability post 2005 when the new patent regime under TRIPS (Trade Related Intellectual Property Rights) comes into force.
"Many of the companies overseas are looking for such tie-ups," said Parswani, hinting that Cadila is in the advanced stages of such an acquisition in the US.
As part of a continuing medical education programme, Cadila had organised a seminar to update leading gastroenterologists in the country on the latest development in the line of treatment for gastric ulcers and esophagitis.
One of the most common health problems worldwide, it is estimated that around 10 percent of people suffer from pain in the abdomen. In India too, this is a widely prevalent problem.
"The most important breakthrough in medicine has been the development of rabeprazole for acid control, which is at the root of the gastroenterological problems," said Parswani.
After two-years of clinical trials, Cadila is getting ready to commercially launch the intravenous (IV) version of its Rabeloc brand of rabeprazole drug.
"Extensive trials are underway and the initial results are very encouraging," said Arun Maseeh, medical head of Cadila Pharmaceuticals.
With the expected launch of the IV drug, Cadila would be the first globally to come out with a drug delivery system that promises quicker and safer treatment management for people who are not able to take rabeprazole drug orally.
The company is also focusing on life sciences to pilot growth.
Source: IANS